national institute of biomedical imaging and bioengineering - listserv

Weekly NIH Funding Opportunities and Notices

NIH Guide for Grants and Contracts

April 12, 2019

Table of Contents (TOC)
Web Version

Notices

The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Southern Regional Workshop on Sexual and Gender Minority (SGM)-Related Research
(NOT-OD-19-097)
National Institutes of Health
Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements
(NOT-OD-19-098)
National Institutes of Health
Notice of Change in Expiration Date of PAR-19-229 "Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial Not Allowed)"
(NOT-AI-19-055)
National Institute of Allergy and Infectious Diseases
Notice of NIAID's Participation in RFA-OD-19-020 "Building Interdisciplinary Research Careers in Women's Health (K12 Clinical Trial Optional)"
(NOT-AI-19-057)
National Institute of Allergy and Infectious Diseases
Notice of NIAMS Participation in PA-18-837: Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
(NOT-AR-19-032)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Notice of Preapplication Webinar for Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models
(NOT-CA-19-040)
National Cancer Institute
Pre-Application Webinar for RFA-CA-19-035, Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)
(NOT-CA-19-041)
National Cancer Institute
Notice of Correction to Eligibility Information in PAR-18-947 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)"
(NOT-CA-19-042)
National Cancer Institute
Notice of Upcoming Webinar for the NCI Office of Cancer Survivorship
(NOT-CA-19-043)
National Cancer Institute
Notice of Correction to Award Information in RFA-CA-19-040 "Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
(NOT-CA-19-044)
National Cancer Institute
Notice of Correction to Award Information in RFA-CA-19-041 "Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)"
(NOT-CA-19-045)
National Cancer Institute
Notice of Correction to RFA-CA-19-047 "SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)"
(NOT-CA-19-046)
National Cancer Institute
Notice of Correction to PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
(NOT-DA-19-031)
National Institute on Drug Abuse
Notice of Correction to RFA-DA-20-002 "Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed)"
(NOT-DA-19-032)
National Institute on Drug Abuse
Notice of NIDCR Participation in Building Interdisciplinary Research Careers in Women's Health (K12 Clinical Trial Optional)
(NOT-DE-19-005)
National Institute of Dental and Craniofacial Research
Notice of NIDDK's Participation in PA-19-196 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31)
(NOT-DK-19-013)
National Institute of Diabetes and Digestive and Kidney Diseases
Notice to Change the Application Due Date for PAR-19-190 - "Advancing Post-Market Surveillance of High-Risk Facilities and Products through Signal detection, Data analysis, and the Review of the State of Quality (U01) Clinical Trial Optional"
(NOT-FD-19-011)
Food and Drug Administration
Notice of Clarification of Institutional Eligibility for PAR-19-102 Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32)
(NOT-GM-19-036)
National Institute of General Medical Sciences
Notice of Clarification of Institutional Eligibility for PAR-19-219 Maximizing Access to Research Careers (T34)
(NOT-GM-19-037)
National Institute of General Medical Sciences
Notice of Clarification of Institutional Eligibility for PAR-19-218 "Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)
(NOT-GM-19-038)
National Institute of General Medical Sciences
NICHD Guidance for Investigator-initiated Basic Experimental Studies Involving Humans (BESH) That Meet NIH's Definition of a Clinical Trial
(NOT-HD-19-012)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Notice of Change to Eligibility Information and Key Dates in RFA-HL-20-009 "BLOODSAFE (UG3/UH3 Clinical Trial Optional)" and Announcement of Availability of FAQs
(NOT-HL-19-691)
National Heart, Lung, and Blood Institute
Pre-Submission Technical Assistance Webinar and Frequently Asked Questions for RFA-HL-20-003: "Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) (UG3/UH3 Clinical Trial Optional)
(NOT-HL-19-692)
National Heart, Lung, and Blood Institute
Pre-Submission Technical Assistance Webinar and Frequently Asked Questions for RFA-HL-20-004 "Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) Research Coordinating Center (U24)"
(NOT-HL-19-693)
National Heart, Lung, and Blood Institute
Notice of Change to Key Dates in RFA-HL-20-010 "BLOODSAFE (U24 Clinical Trial Not Allowed)" (NOT-HL-19-694)
National Heart, Lung, and Blood Institute
Oversight and Monitoring of Clinical Research funded by the NIMH
(NOT-MH-19-027)
National Institute of Mental Health
Notice of Intent to Publish the Reissuance of "RFA-NS-19-025" "HEAL Initiative: Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (U24 Clinical Trial Not Allowed)"
(NOT-NS-19-051)
National Institute of Neurological Disorders and Stroke
Notice of Correction to Application Types Allowed for RFA-NS-19-017 "HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)"
(NOT-NS-19-052)
National Institute of Neurological Disorders and Stroke
Notice of Change to Key Dates for RFA-NS-19-016 "HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)"
(NOT-NS-19-053)
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Nursing Research
Notice of Change to Key Dates for RFA-NS-19-017 "HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)"
(NOT-NS-19-054)
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Nursing Research
Office of Research on Women's Health
Notice of Change to Key Dates for RFA-NS-19-018 "HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)"
(NOT-NS-19-055)
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Nursing Research
Office of Research on Women's Health
Notice of Change to Key Dates for RFA-EB-18-003 "HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)"
(NOT-NS-19-056)
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
National Cancer Institute
National Eye Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
Notice of Change to Response Date for NOT-NS-19-045 " Request for Information: Soliciting Input on How Best to Advance Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Research"
(NOT-NS-19-057)
National Institute of Neurological Disorders and Stroke
Updates for PAR-18-812 Occupational Safety and Health Research (R01)
(NOT-OH-19-003)
National Institute for Occupational Safety and Health
Updates for PAR-18-797 Occupational Safety and Health Research (R03)
(NOT-OH-19-004)
National Institute for Occupational Safety and Health
Updates for PAR-18-798 NIOSH Exploratory/Developmental Research Grant Program (R21)
(NOT-OH-19-005)
National Institute for Occupational Safety and Health

Requests for Applications

Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (U01 Clinical Trial Not Allowed)
(RFA-AI-19-030)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 22, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
(RFA-CA-19-047)
National Cancer Institute
Application Receipt Date(s): August 9, 2019, by 5:00 PM local time of applicant organization. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Oral Health in People Living with HIV and Additional Non-Communicable Diseases (R01 Clinical Trial Not Allowed)
(RFA-DE-20-001)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): July 29, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this Funding Opportunity Announcement.
Convener and organizer of activities and engagements focused on the development of medical products and related processes, surveillance, and policies relevant to ongoing public health activities. (U01) Clinical Trial Not Allowed
(RFA-FD-19-013)
Food and Drug Administration
Application Receipt Date(s): June 11, 2019 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
Late-Stage Implementation Research Addressing Hypertension in Low- and Middle-Income Countries: Scaling Up Proven-Effective Interventions (UG3/UH3 Clinical Trial Optional)
(RFA-HL-20-005)
National Heart, Lung, and Blood Institute
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): July 8, 2019 by 5:00 PM local time of applicant organization.
BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
(RFA-MH-20-120)
National Institute of Mental Health
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Neurological Disorders and Stroke
Office of Behavioral and Social Science Research
Application Receipt Date(s): September 6, 2019 and June 11, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.
BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)
(RFA-MH-20-135)
National Institute of Mental Health
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): September 27, 2019 and September 30, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.
Building Interdisciplinary Research Careers in Women's Health (BIRCWH); K12 Clinical Trial Optional
(RFA-OD-19-020)
Office of Research on Women's Health
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
Application Receipt Date(s): May 29, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Program Announcements

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
(PAR-19-242)
National Cancer Institute
Application Receipt/Submission Date(s): June 18, 2019; June 17, 2020; June 17, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
International Bioethics Research Training Program (D43 Clinical Trial Optional)
(PAR-19-243)
John E. Fogarty International Center
National Human Genome Research Institute
Application Receipt/Submission Date(s): June 4, 2019; June 4, 2020, June 4, 2021), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)
(PAR-19-244)
John E. Fogarty International Center
National Human Genome Research Institute
National Institute of Allergy and Infectious Diseases
Application Receipt/Submission Date(s): June 4, 2019, June 4, 2020, June 4, 2021.
Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)
(PAR-19-246)
National Institute on Drug Abuse
Application Receipt/Submission Date(s): June 12, 2019; July 15, 2020; July 15, 2021 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the standard application due dates.
Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 Clinical Trial Not Allowed)
(PAR-19-247)
National Institute of Allergy and Infectious Diseases
Application Receipt/Submission Date(s): June 18, 2019, June 18, 2020, June 18, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R01 Clinical Trial Not Allowed)
(PAR-19-248)
National Institute of Allergy and Infectious Diseases
Application Receipt/Submission Date(s): June 10, 2019, June 10, 2020, and June 10,2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Processes (R01 Clinical Trial Not Allowed)
(PAR-19-249)
National Institute on Aging
National Institute of Environmental Health Sciences
Office of Behavioral and Social Science Research
Application Receipt/Submission Date(s): July 8, 2019; November 4, 2019; March 9, 2020; July 7 6 , 2020; November 9, 2020; and March 8, 2021, by5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Populations (R01 Clinical Trial Optional)
(PAR-19-250)
National Institute of Environmental Health Sciences
National Institute on Aging
National Institute on Minority Health and Health Disparities
National Institute of Nursing
Research Office of Behavioral and Social Science Research
Application Receipt/Submission Date(s): July 8, 2019, November 4, 2019, March 9, 2020, July 7, 2020, November 9, 2020, March 8, 2021, apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)
(PAR-19-251)
National Cancer Institute
National Institute of Environmental Health Sciences
Application Receipt/Submission Date(s): July 2, 2019; November 6, 2019; July 2, 2020; November 6, 2020; July 8, 2021; November 8, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)
(PAR-19-252)
National Cancer Institute
National Institute of Environmental Health Sciences
Application Receipt/Submission Date(s): July 2, 2019; November 6, 2019; July 2, 2020; November 6, 2020; July 8, 2021; November 8, 2021 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)
(PAR-19-253)
National Institute of General Medical Sciences
National Center for Complementary and Integrative Health
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
Exploratory Research for Technology Development (R21 - Clinical Trial Not Allowed)
(PAR-19-254)
National Institute of General Medical Sciences
National Center for Complementary and Integrative Health
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.